Lion TCR Files IPO Prospectus Following Landmark Deal at the 14th China Bioindustry Conference in Guangzhou’s Sino-Singapore Knowledge City

Singapore and Guangzhou, China, June 13, 2022 /PRNewswire/ -- The 14th China Bio-Industry Conference opened in Guangzhou. Dr. Peng Xiaoming, CEO of Guangzhou Laien Biological Medicine Co., Ltd. (Laien Bio), was invited to attend the Guanzhou International BioObject Forum.Dr. Peng Xiaoming signed the agreement with Ms. Xian Yinsong, Deputy Secretary of the Guangzhou Development District Working Committee and Mayor of Huangpu District, on the "Laien Bio Innovative Drug Research and Development and Production Base Project" at the forum. The Laien Bio innovative drug R&D and production base is planned to be located in the Sino-Singapore Guangzhou Knowledge City. It will become a comprehensive platform integrating TCR-T cell therapy research, production, and clinical applications, providing strong support for the company’s further innovation and development in China. A total of nine projects were signed at this forum, which are committed to creating a world-class biotechnology innovation industrial cluster.

Signing Ceremony Scene

Sino-Singapore Guangzhou Knowledge City

This conference is the largest, highest-level, and most influential industry event in China's biotechnology sector. It serves as an important window for the public to understand the development direction of biotechnology and the biotechnology industry. It is also a crucial platform for communication and collaboration between industry, academia, and research. Moreover, it has become an essential vehicle for mobilizing resources from all sectors of society to jointly promote the healthy development of the industry, playing a positive role in advancing China's biotechnology industry.

This conference has invited Nobel Prize winners and other top experts from the global biotechnology industry, as well as academic, industrial, and research sectors in the biological field to participate. With a gathering of leading figures, they will jointly discuss public health.、Issues such as human health and the bioeconomy, exploring the latest development trends in the global biotechnology industry.The conference received high attention and support from leaders at all levels.Leaders of the Guangdong Provincial Government and the Guangzhou Municipal Government also attended the opening ceremony. At the same time, top academicians, experts, scholars in the global biotechnology field, as well as renowned entrepreneurs from the biotechnology industry and investment sectors, were invited to attend this conference.

Lion TCR, a Singapore-based biotech company, is committed to developing T-cell immunotherapies for virus-related cancers and infectious diseases. As the global pioneer and leader in utilizing HBV-specific TCR-T cell therapy for liver cancer treatment, its product pipeline also includes chronic hepatitis B infection, liver fibrosis, and cirrhosis, among others. Meanwhile, Lion TCR is dedicated to building TCR discovery platforms related to TCR-T, autologous and allogeneic cell therapy platforms, and bispecific molecule platforms for treating various solid tumors such as liver cancer, gastric cancer, nasopharyngeal cancer, cervical cancer, and infectious diseases like chronic hepatitis B.

Lion TCR has obtained the IND clinical approval for an international multicenter Phase 1b/2 trial granted by the U.S. Food and Drug Administration (FDA). This is the world’s first FDA-approved international multicenter clinical trial utilizing TCR-T therapy to treat hepatitis B virus-related hepatocellular carcinoma. Lion TCR has also received Fast Track designation and Orphan Drug Designation (ODD) from the FDA. Former FDA review authority, Academician Zhang Dan, once stated: "Receiving both Fast Track and ODD designations will provide Lion TCR with an accelerated pathway for obtaining FDA regulatory approval and market entry for its product, potentially saving one to three years. It is highly likely to become another drug, after BeiGene, to quickly reach the market leveraging both Fast Track and ODD designations."

Laien Bio actively participates in Guangzhou's efforts to build a cell and gene industry ecosystem in the Greater Bay Area, promoting the establishment and development of a biopharmaceutical industry chain that includes new drug R&D, clinical applications, and GMP-level cell production.Relevant LeadersEmphasized at the meeting：“Guangdong Province is the pioneer of China's reform and opening-up and a strategic leader in implementing development strategies. The biotechnology industry is also one of the key areas for high-quality development in Guangdong Province. A specific set of ten innovative biomedicine policies has been introduced, along with strong biotechnology research and development institutions and an active biotechnology industrial cluster.。”Guangzhou Laien Biological Medicine Co., Ltd. is committed to developing into a biotech unicorn that has grown under the care of both the Chinese and Singaporean governments. By enabling its products to achieve technological iteration and updates in Guangzhou, the company aims to rely on Guangzhou, establish itself in the Greater Bay Area, contribute to a Healthy China, and expand towards Southeast Asia and the world. It actively practices the conference theme of "Innovation, Openness, Integration, and Embracing the New Era of the Bioeconomy."